Clinical data | |
---|---|
Pronunciation | /lænˈsoʊprəzoʊl/ lan-SOH-prə-zohl |
Trade names | Prevacid, others |
Other names | AG 1749 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a695020 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Proton pump inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80% or more |
Protein binding | 97% |
Metabolism | Liver (CYP3A4- and CYP2C19-mediated) |
Elimination half-life | 1.0–1.5 hours |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.173.220 |
Chemical and physical data | |
Formula | C16H14F3N3O2S |
Molar mass | 369.36 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
Melting point | 178 °C (352 °F) (decomposes) |
| |
| |
(verify) |
Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid.[4] It is a proton pump inhibitor (PPI), used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome.[5] Its effectiveness is similar to that of other PPIs.[6] It is taken by mouth.[4] Onset is over a few hours and effects last up to a couple of days.[4]
Common side effects include constipation, abdominal pain, and nausea.[4][3] Serious side effects may include osteoporosis, low blood magnesium, Clostridioides difficile infection, and pneumonia.[4][3] Use in pregnancy and breastfeeding is of unclear safety.[1] It works by blocking H+/K+-ATPase in the parietal cells of the stomach.[4]
Lansoprazole was patented in 1984 and came into medical use in 1992.[7] It is available as a generic medication.[5] In 2022, it was the 224th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[8][9]
Lansoprazole label
was invoked but never defined (see the help page).